Corimmun, a Germany-based drug development company backed by High-Tech Gründerfonds,, has been sold to Janssen-Cilag, part of the Janssen Pharmaceutical Companies of US-based pharmaceutical group Johnson & Johnson.
Corimmun received €680,000 ($855,000) of funding in 2008 from High-Tech Gründerfonds, Bayern Kapital and BioM in 2007.
Corimmun’s main product is Cor-1, a peptide for the treatment of heart failure.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
